GCT (NASDAQ: GCT) planned sale of 800,000 Class A shares under Rule 144
Rhea-AI Filing Summary
A holder of GCT Class A ordinary shares has filed a notice of proposed sale of 800,000 shares under Rule 144. The shares are Class A ordinary shares with a par value of $0.05 per share, to be sold through Futu Securities International (Hong Kong) Ltd. on the NASDAQ market. The filing lists an aggregate market value of $32,760,000 for the 800,000 shares and notes that approximately 28,980,012 shares of this class are outstanding.
The shares to be sold were acquired on 07/01/2020 from the issuer as equity compensation, with “compensation” described as the nature of payment. The approximate date of sale is stated as 01/07/2026, indicating an intention to dispose of this block over time consistent with Rule 144 requirements. The signer represents that they are not aware of any undisclosed material adverse information about the issuer’s operations.
Positive
- None.
Negative
- None.
Insights
Large planned Rule 144 sale in GCT, neutral but notable in size.
This notice outlines a planned Rule 144 sale of $32,760,000 worth of GCT Class A ordinary shares, totaling 800,000 shares. These shares were granted as equity compensation on 07/01/2020 and are now slated for potential sale on or after an approximate date of 01/07/2026, using Futu Securities International as broker on NASDAQ.
The filing also states that 28,980,012 Class A ordinary shares are outstanding, so this represents a meaningful but not dominant block relative to that baseline. Rule 144 sales are a standard pathway for holders of restricted or control securities to sell into the market, and the representation that the seller knows no undisclosed material adverse information is part of that framework. Actual market impact, if any, would depend on how and when these shares are placed over time.
FAQ
Does the seller make any representation about undisclosed adverse information on GCT?
Yes. By signing, the person for whose account the securities are to be sold represents that they do not know any material adverse information about the issuer’s current or prospective operations that has not been publicly disclosed.